Fusion Pharmaceuticals Inc. (FUSN)

NASDAQ: FUSN · IEX Real-Time Price · USD
21.32
+0.02 (0.09%)
At close: Mar 28, 2024, 4:00 PM
21.25
-0.07 (-0.31%)
After-hours: Mar 28, 2024, 6:28 PM EDT
0.09%
Market Cap 1.81B
Revenue (ttm) 2.07M
Net Income (ttm) -94.90M
Shares Out 84.69M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,564,243
Open 21.30
Previous Close 21.30
Day's Range 21.25 - 21.37
52-Week Range 2.31 - 21.44
Beta -0.85
Analysts Hold
Price Target 20.86 (-2.16%)
Earnings Date Mar 20, 2024

About FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved check... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 101
Stock Exchange NASDAQ
Ticker Symbol FUSN
Full Company Profile

Financial Performance

In 2023, FUSN's revenue was $2.07 million, an increase of 41.55% compared to the previous year's $1.46 million. Losses were -$94.90 million, 8.32% more than in 2022.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for FUSN stock is "Hold." The 12-month stock price forecast is $20.86, which is a decrease of -2.16% from the latest price.

Price Target
$20.86
(-2.16% downside)
Analyst Consensus: Hold
Stock Forecasts

News

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN

NEW YORK , March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securit...

2 days ago - PRNewsWire

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expect...

8 days ago - PRNewsWire

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Fusion Pharmaceu...

9 days ago - Business Wire

FUSN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Fusion Pharmaceuticals Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) to AstraZeneca is fair to Fusion shareholders....

10 days ago - Business Wire

AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion

AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.

Other symbols: AZN
10 days ago - Market Watch

AstraZeneca to buy Fusion Pharma for $2 billion in cash

AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.

Other symbols: AZN
10 days ago - Reuters

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer

Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities Fusion sharehold...

10 days ago - PRNewsWire

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAMILTON, ON and BOSTON, March 6, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

22 days ago - PRNewsWire

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

HAMILTON, ON and BOSTON , March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

23 days ago - PRNewsWire

Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences

HAMILTON, ON and BOSTON , Feb. 26, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

4 weeks ago - PRNewsWire

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

FPI-2265 positioned to be the first approved PSMA targeted alpha therapy HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology co...

5 weeks ago - PRNewsWire

Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

HAMILTON, ON and BOSTON , Feb. 7, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

7 weeks ago - PRNewsWire

Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates

Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) Achieved target enrollme...

3 months ago - PRNewsWire

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic...

Other symbols: BMYLLY
3 months ago - Market Watch

10 ‘better values' in the stock market, selected for the next two years

Since market valuations are always changing, along with outlooks for corporate revenue and earnings, any list of favored stocks is only a snapshot. Repeating the same analysis in the near term might l...

4 months ago - Market Watch

BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology

OTTAWA, Ontario--(BUSINESS WIRE)--BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology.

Other symbols: BWXT
4 months ago - Business Wire

Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration

Collaboration enables Fusion to produce high purity actinium-225 at Company's GMP manufacturing facility Agreement furthers BWXT Medical's position as a global leader in medical isotope supply HAMILTO...

Other symbols: BWXT
4 months ago - PRNewsWire

Fusion Pharmaceuticals to Present at Upcoming Investor Conferences

HAMILTON, ON and BOSTON , Nov. 8, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

5 months ago - PRNewsWire

Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates

Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around year-end 2023 FPI-2068, a bis...

5 months ago - PRNewsWire

Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors

HAMILTON, ON and BOSTON , Oct. 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

5 months ago - PRNewsWire

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

Data presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics FPI-2068 demonstrates anti-tumor activity in colorectal and lung tumor xenograft mouse m...

Other symbols: AZN
6 months ago - PRNewsWire

Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences

HAMILTON, ON and BOSTON , Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

7 months ago - PRNewsWire

Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates

FPI-2265 (Ac-PSMA I&T) IND transferred to Fusion; program is enrolling patients and on track for Q1 2024 update Preliminary clinical data presented at the Society of Nuclear Medicine and Molecular Ima...

8 months ago - PRNewsWire

Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in ...

9 months ago - PRNewsWire

Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit

HAMILTON, ON and BOSTON , June 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...

10 months ago - PRNewsWire